Express Scripts Includes Propeller Health in Its First Formulary for Digital Health Solutions

Propeller is the only digital health solution for chronic respiratory disease to be included in the first release of the formulary, which will help people with chronic illnesses take control of their health

MADISON, Wis., December 12, 2019 – Express Scripts today announced its first formulary for digital and mobile health apps and devices, which will include Propeller Health’s digital health platform for asthma and COPD.

Starting in January 2020, the Express Scripts Digital Health Formulary will initially include 15 digital health solutions that aid in the management of eight of the country’s most common chronic conditions: diabetes, prediabetes, hypertension, asthma, pulmonary disease, depression, anxiety and insomnia.

These solutions help patients manage their conditions in a variety of ways, including:

  • Allowing a pharmacist or nurse to remotely monitor a patient’s use of a drug therapy;
  • Connecting with a diagnostic device that provides patients or their caregivers with vital information and notifies them of potential concerns;
  • Offering virtual personal coaching from a health or wellness professional; and
  • Providing virtual support from a patient’s peer.

According to Express Scripts, the Digital Health Formulary enables participating health plans and employers to increase patients’ access to emerging products and technologies simply and affordably. People who use a program on the Digital Health Formulary will receive support from Express Scripts specialist pharmacists to ensure appropriate use of the technology.

“The Express Scripts Digital Health Formulary will do for the developing digital healthcare industry what our drug formularies have achieved for prescription medications for more than 20 years – access, choice and value for payers and patients,” said Mark Bini, chief patient experience officer, Express Scripts. “We are setting the bar high for clinical effectiveness, user experience and financial value for these solutions, while also combining coverage into the pharmacy benefit and providing patients with expert support from Express Scripts specialist pharmacists.”

Express Scripts reviewed more than 70 digital health products for this first round of the formulary, in a four-stage process that tested each product for:

  • Clinical effectiveness
  • User experience
  • Security and privacy compliance
  • Value and affordability

Over the course of a year, pulmonary remote monitoring with the Propeller Health program – in concert with Express Scripts pulmonary specialist pharmacist support – led to improvements in symptoms, an 82% decrease in the use of rescue inhalers and a 10% increase in adherence to controller medications that help to prevent adverse asthma symptoms and exacerbations.

“The Express Scripts Digital Health Formulary is an important and necessary pathway that will help ensure people with chronic disease can access clinically proven digital health solutions,” said David Van Sickle, CEO and co-founder of Propeller Health. “We have carefully developed our technology over nine years to deliver safe and effective care to people with chronic respiratory disease, and inclusion on the Express Scripts Digital Health Formulary is a recognition of the value we provide to patients and plans.”

“It’s our job to find the right digital health solutions for our clients and patients, and then make sure patients use these solutions effectively,” said Bini. “With the Express Scripts Digital Health Formulary, we’ve created more than just a list of approved programs or a vendor management process. We built a foundation for the future of care and pharmacy that will deliver better access, affordability and health.”

About Propeller Health

Propeller Health is a leading digital health company dedicated to making life better for every person with chronic respiratory disease. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. Propeller Health is a wholly owned subsidiary of ResMed (NYSE: RMD, ASX: RMD). For more information, visit www.propellerhealth.com.

 

###

 

For media

Rachel Fields

+ 1 630.901.8625

[email protected]

 

For investors

Amy Wakeham

+ 1 858.836.5000

[email protected]